Loading...
XKRX
053030
Market cap380mUSD
Jul 29, Last price  
17,090.00KRW
1D
0.29%
1Q
10.26%
Jan 2017
0.83%
IPO
182.95%
Name

Binex Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
P/S
4.06
EPS
Div Yield, %
Shrs. gr., 5y
-0.17%
Rev. gr., 5y
0.75%
Revenues
130.05b
-16.00%
55,128,608,54057,296,767,00071,138,024,95480,924,373,09778,026,379,736104,043,177,118125,258,578,553132,976,386,577134,399,279,256156,677,024,474154,824,775,515130,050,545,610
Net income
-35.07b
L
-7,444,788,270-4,069,080,780-6,812,622,549-3,004,864,364-11,294,772,9596,337,273,6568,504,132,8616,412,227,80019,094,152,20012,444,529,9304,670,748,390-35,070,820,730
CFO
-9.43b
L
-277,270,000-1,847,507,250-4,497,193,9693,798,796,9948,135,901,45413,560,867,77210,784,653,85019,853,740,08626,574,623,86417,062,098,0933,777,776,700-9,425,558,790
Dividend
Dec 29, 2008200 KRW/sh
Earnings
Aug 12, 2025

Profile

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
IPO date
Aug 07, 2001
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
130,050,546
-16.00%
154,824,776
-1.18%
156,677,024
16.58%
Cost of revenue
146,239,960
153,285,038
126,125,354
Unusual Expense (Income)
NOPBT
(16,189,414)
1,539,737
30,551,670
NOPBT Margin
0.99%
19.50%
Operating Taxes
(3,747,349)
311,129
2,868,264
Tax Rate
20.21%
9.39%
NOPAT
(12,442,065)
1,228,608
27,683,406
Net income
(35,070,821)
-850.86%
4,670,748
-62.47%
12,444,530
-34.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
(12,000,000)
BB yield
4.13%
Debt
Debt current
61,176,330
47,928,780
54,619,479
Long-term debt
11,022,939
12,332,550
3,065,087
Deferred revenue
Other long-term liabilities
688,902
754,767
1,257,563
Net debt
15,506,852
16,378,763
(29,370,108)
Cash flow
Cash from operating activities
(9,425,559)
3,777,777
17,062,098
CAPEX
(10,366,068)
(7,747,267)
(36,453,163)
Cash from investing activities
(2,853,403)
(14,179,951)
(39,124,800)
Cash from financing activities
29,840,754
(12,573,199)
3,223,216
FCF
(8,769,235)
(19,765,928)
7,273,392
Balance
Cash
27,793,022
13,453,694
38,203,107
Long term investments
28,899,394
30,428,873
48,851,566
Excess cash
50,189,889
36,141,328
79,220,822
Stockholders' equity
37,294,860
62,598,481
63,525,945
Invested Capital
210,804,866
199,445,975
182,968,319
ROIC
0.64%
15.03%
ROCE
0.65%
12.14%
EV
Common stock shares outstanding
30,918
32,497
30,925
Price
18,340.00
104.92%
8,950.00
-22.51%
11,550.00
-24.01%
Market cap
567,041,567
94.96%
290,845,751
-18.57%
357,178,391
-24.46%
EV
582,794,586
317,272,276
328,485,409
EBITDA
(3,757,227)
10,520,412
38,852,585
EV/EBITDA
30.16
8.45
Interest
2,296,389
2,061,625
Interest/NOPBT
6.75%